|Home | About | Journals | Submit | Contact Us | Français|
A robust and complex inflammatory cascade is known to be a prominent component of secondary injury following spinal cord injury (SCI). Specifically, the concept of trauma-induced autoimmunity has linked the lymphocyte population with neural tissue injury and neurologic deficit. FTY720, a sphingosine receptor modulator that sequesters lymphocytes in secondary lymphoid organs, has been shown to be effective in the treatment of a variety of experimental autoimmune disorders. Accordingly, by reducing lymphocyte infiltration into the spinal cord following SCI, this novel immunomodulator may enhance tissue preservation and functional recovery. In the present study, a moderate to severe contusion SCI was simulated in adult Long-Evans hooded rats. Using flow cytometry we showed that daily FTY720 treatment dramatically reduced T-cell infiltration into the SCI lesion site at 4 and 7 days post-injury, while other inflammatory cell populations were relatively unaltered. To assess functional recovery, three groups of injured animals (treated, vehicle, and injury only) were evaluated weekly for hindlimb recovery. Animals in the treated group consistently exhibited higher functional scores than animals in the control groups after 2 weeks post-injury. This finding was associated with a greater degree of white matter sparing at the lesion epicenter when cords were later sectioned and stained. Furthermore, treated animals were found to exhibit improved bladder function and a reduced incidence of hemorrhagic cystitis compared to control counterparts. Collectively these results demonstrate the neuroprotective potential of FTY720 treatment after experimental SCI.
The pathophysiology of spinal cord injury (SCI) has classically been partitioned into primary and secondary injury processes. After the initial primary injury, secondary injury encompasses an insidious cascade of cellular and biochemical events, the magnitude of which is rivaled only by its complexity. Within this milieu of events, inflammation has been identified as an important component of secondary injury, and numerous cell populations have been implicated as mediators of inflammation. Among these cells, lymphocytes have generated interest due to their key involvement in the concept of trauma-induced autoimmunity (Popovich et al., 1996; Gonzalez et al., 2003; Ankeny et al., 2006). This concept is based on the hypothesis that traumatic injury results in the release of neural self-antigens and subsequent immunological activation. In support of this possibility, injection into naïve animals of T cells isolated from rats subjected to SCI resulted in central nervous system (CNS) tissue injury and neurological deficit (Popovich et al., 1996).
Many of these studies of SCI and autoimmunity have drawn on parallels from our current knowledge of multiple sclerosis (MS), and the animal model of experimental autoimmune encephalomyelitis. In both of these processes, T cells are known to infiltrate the CNS, resulting in demyelination and neurologic dysfunction. Targeted therapies for MS have therefore focused on immunomodulation, specifically in the T-cell population.
FTY720 administration is one of the newest immunomodulatory therapies for MS, and is currently undergoing phase III clinical trials as monotherapy. FTY720 is a chemical derivative of the fungal metabolite myriocin, and in its phosphorylated form acts as a sphingosine-1-phosphate (S1P) mimetic and agonist of the S1P receptor (Brinkmann et al., 2002). Several groups have shown that administration of FTY720 results in a significant reduction in peripheral lymphocyte counts (Pinschewer et al., 2000; Brinkmann et al., 2000; Chiba et al., 1998). It has been postulated that FTY720 induces this lymphopenia by preventing lymphocyte egress from peripheral lymphoid organs. Once FTY720 binds to the S1P receptor, internalization and subsequent degradation of the receptor occurs (Matloubian et al., 2004). This degradation thereby eliminates the S1P signal necessary for lymphocyte egress and prevents recirculation into the CNS (Brinkmann et al., 2002; Matloubian et al., 2004; Mandala et al., 2002).
Independent of this ability to prevent lymphocyte migration, FTY720 has also been shown to have other cytoprotective capabilities. Studies have shown that FTY720 can prevent apoptosis in neural cells and act on endothelial cells to preserve vascular integrity (Brinkmann et al., 2004; Fujino et al., 2003; Coelho et al., 2007). The exact mechanisms of these effects are still under investigation.
In this study we examined the efficacy of FTY720 in a moderate to severe contusion model of SCI. We hypothesized that administration of FTY720 would reduce infiltration of T cells into the spinal cord lesion site and enhance functional recovery after SCI. Our results indeed demonstrate the efficacy of FTY720 in a model of CNS trauma, and show that administration enhances tissue preservation and functional outcome after SCI.
Adult Long-Evans hooded rats (70±10 days of age) were used for the spinal cord injury protocols. All surgical and postoperative care procedures were performed in accordance with the Virginia Commonwealth University Institutional Animal Care and Use Committee. The animals were endotracheally intubated and maintained under inhalational anesthesia (2.5% isoflurane) during all surgical procedures. Depth of anesthesia was tested during surgical procedures by tail pinch and observation for reflexive movements. Body temperature was kept normothermic using a homeothermic blanket. Using sterile technique, a dorsal midline incision was made over the mid-thoracic spine and a standard T8 laminectomy was performed. The animals were then placed in a spinal frame and the exposed cord was contused with the MASCIS impactor using a 10-g weight dropped from a height of 25mm. Animal injuries with unacceptable impact parameters were excluded from the study. Immediately after injury, the animals were randomized to receive an IP injection of FTY720 (1mg/kg) (Cayman Chemical, Ann Arbor, MI) solubilized in 0.1% DMSO (Sigma-Aldrich, St Louis, MO), vehicle (0.1% DMSO), or no injection (injury only). Animals were then allowed to recover in a separate recovery area with a warming blanket.
All animals received prophylactic gentamicin (Butler Health Supply, Dublin, OH) 5mg/kg before surgery and daily thereafter for 7 days. Manual bladder expression was performed three times daily for the first week after surgery and two times daily thereafter until spontaneous micturition was re-established. Urine volumes were recorded at each collection and spontaneous micturition was defined as established when daily volumes collected were<2mL total for 3 consecutive days. Expressed urine was also monitored for evidence of urinary tract infection by the presence of elevated urine pH or leukocytes, and treated with a 5-day course of gentamicin (5mg/kg) if diagnosed.
Postoperatively, all animals were given easy access to food and water and housed two per cage. Analgesic medication (Tylenol oral suspension, 2mg/mL) was mixed into the drinking water and administered for the first 3 days post-injury (dpi).
For flow cytometry, injured animals received daily IP injections of either FTY720 (n=5) or vehicle (n=5) until sacrificed. On the first, fourth, and seventh days post-injury, animals were sacrificed with a lethal dose of pentobarbital (Sigma-Aldrich). A 1-cm section of the cord peri-centric to the impact site as well as the spleen were then harvested. Both the cord and spleen tissue were individually dissociated by passage through a 70-μm filter and washed twice with PBS. Erythrocytes were lysed with Tris-buffered ammonium chloride (PharmLyse; BD Biosciences, San Jose, CA). Leukocytes were identified as round, phase-bright entities with a diameter of ~10μm that excluded trypan blue and were enumerated with a hemocytometer. Antibodies used for phenotypic analysis were anti-CD3, -CD4, -CD8α, -CD11b, and -His48, and were biotinylated or conjugated to R-phycoerythrin or fluorescein isothiocyanate. Streptavidin conjugated to allophycocyanin was used for the detection of biotinylated antibodies (all from BD Biosciences). Approximately 1×106 cells were stained with 0.5μg of each monoclonal antibody as previously described (Graf et al., 2001). Cells were then fixed and permeabilized (Cytofix/Cytoperm; BD Biosciences), washed with PBS, and stained with the DNA-specific dye 7-aminoactinomycin (7-AAD; 10μg/mL). Three-color fluorometric analysis was performed using a FACSCanto flow cytometer (BD Biosciences). Cells were identified as 7-AAD-positive events on a FL3 versus side-scatter histogram as described by Lipton and associates (2005), and 10,000 7-AAD-positive events were analyzed. T-cell subsets were identified as CD3+/CD4+ or CD3+/CD8+ double-positive cells. Monocytes and granulocytes were identified as CD11b+ and His48+ cells, respectively.
All animals were gentled in the open field twice a day for 7 consecutive days prior to injury. Animals randomized to the treated group (n=11) received daily IP injections of FTY720 1mg/kg for 4 weeks. Vehicle-group animals (n=10) received daily IP injections of 0.1% DMSO for the same time period. The injury-only group (n=9) received no injections. T8 laminectomies were performed on sham animals (n=2), but no injuries were performed and no injections administered. At 2 and 7 dpi and once weekly thereafter for a total of 6 weeks, the rats were placed in the open field and observed for 4min. Two researchers blinded to treatment group observed the animals in open-field testing. Gross locomotor recovery after SCI was assessed using the Basso-Beattie-Bresnahan (BBB) locomotor rating scale (Basso et al., 1995). Observations for each hindlimb were scored and averaged to provide a single score for each animal per session. All data were collected within the 4-min period. Once a plateau in locomotor recovery was evident (≥28 dpi), a frequency analysis of plantar stepping and coordination was performed across all groups.
All animals were also tested on the inclined plane task. This task evaluates the animal's ability to maintain a horizontal body position on an inclined board. The angle of the board is incrementally raised until the animal is no longer able to maintain the horizontal position. Performance on the inclined plane correlates with the integrity of the rubrospinal tract (and other nonpyramidal pathways) after SCI. During testing, animals were placed in the right- and left-side-up positions. The maximum angle at which the animal was able to maintain position on the board for 10sec was recorded for each side. Data were recorded as the average of the two sides to obtain a single score for each animal per session.
At 6 weeks post-injury, the animals were sacrificed with a lethal dose of pentobarbital and perfused transcardially with 125mL of PBS (pH 7.4), followed by 250mL of 4% paraformaldehyde. Spinal cords were harvested and post-fixed for 2h in the same fixative before being immersed in PBS (0.2M) overnight. The cords were then cryoprotected in 30% sucrose for 48h. FTY720-treated (n=9) and vehicle-treated (n=8) cords were blocked and embedded together in optimal cutting temperature compound (Thermo Shandon, Pittsburgh, PA), and sectioned at a thickness of 20μm. A complete series of axial sections spanning the injury site was collected and stained with eriochrome cyanine to assess for myelin sparing. Also, axial sections peripheral to the injury epicenter were collected at 0.5-mm intervals and stained with eriochrome cyanine. For each spinal cord, the lesion epicenter was qualitatively defined by a blinded researcher as the section containing the least amount of intact tissue. This section and sections located 100μm rostral and caudal were chosen to quantify the area of spared myelin at the epicenter. Light microscopy at 25× magnification was used to visualize the sections, and images were obtained with an Olympus DP12 camera (Olympus America Inc., Center Valley, PA). These images were then imported into the NIH Image J program and white matter sparing analysis was performed by a blinded observer. The percentage of myelin spared was calculated by manually outlining the spared white matter regions, which then generated an area as denoted by the number of pixels. This area was then divided by the total cross-sectional area of the axial section. The average of the three sections was used to denote the percentage of myelin spared at the injury epicenter. In the same fashion as described above, sections rostral and caudal to the epicenter at 0.5-mm intervals were analyzed for white matter sparing.
Data are reported as means±standard error of the mean. All statistical analyses were performed using statistical software (SPSS 16.0; SPSS Inc., Chicago, IL). Data from open-field, inclined plane, and urine volumes were analyzed by repeated measures two-way ANOVA with the post-hoc pairwise comparison test. Days to spontaneous voiding was analyzed by one-way ANOVA with post-hoc Tukey analysis. Fisher's exact test was used for hematuria incidence and locomotor frequency analysis. For flow cytometry and myelin sparing analysis, data were compared using Student's t-test. Differences with a p value<0.05 were considered statistically significant.
FTY720 is known to be a potent immunomodulator and numerous reports have shown that administration reduces peripheral lymphocyte circulation (Pinschewer et al., 2000; Brinkmann et al., 2000; Chiba et al., 1998). In order to establish the efficacy of FTY720 treatment in a model of SCI, we quantified inflammatory cell infiltration into the injured spinal cord using flow cytometry. Data from this analysis showed that FTY720 administration significantly reduced the infiltration of CD4+ T-helper cells to the spinal cord lesion site compared to vehicle administration at 4 dpi (7.56±0.25 versus 3.80±0.5; p<0.001; Fig. 1D). This response was similar to the reduction seen in the CD8+ cytotoxic T-cell population (7.80±1.01 versus 3.68±1.31; p<0.01; Fig. 1D). At 7 dpi, a similar reduction was seen in the CD4+ T-helper cells (10.01±1.40 versus 6.40±0.72; p<0.05), and in the CD8+ cytotoxic T-cell population (8.51±0.51 versus 6.01±0.40; p<0.01). However, there was no difference noted in either cell population at 1 dpi. For all time points, no statistical difference was noted between vehicle and FTY720 administration in the spleen tissue.
In order to evaluate for other inflammatory cell populations infiltrating the spinal cord after injury, antibody labeling for His48 (granulocytes) and CD11b (monocytes) was performed (data not shown). A slight trend toward reduction was observed with FTY720 administration in the His48+(24±2.4 versus 20.2±1.9; p=0.29) and the CD11b+ cell populations (40.3±1.47 versus 32.8±7.5; p=0.38). However, neither of these differences were statistically significant, suggesting that FTY720 specifically inhibits T-cell infiltration.
Once we established the efficacy of FTY720 in a model of SCI, our next step was to determine the extent to which administration would impact functional recovery. Hindlimb function was therefore evaluated for 6 weeks after SCI using the open-field and inclined-plane tests. During the acute and intermediate recovery stages, no differences in BBB locomotor scores were noted among groups (Fig. 2A). However, by 21 dpi the mean BBB score in the FTY720-treated animals surpassed those of the vehicle animals by 1.4 (11.5 versus 10.1; p<0.05). Moreover, this difference was sustained throughout the remainder of the analysis, even after drug treatment was discontinued at 28 dpi. By the end of the analysis, the mean difference between treated and vehicle groups was 1.5 (12.5 versus 11.0; p<0.005). No differences were noted between the vehicle and injury-only groups at any time point.
A frequency analysis of the open-field data is shown in Table 1, and reflects differences in locomotor milestones between the groups once recovery reached a plateau. For each time point post-injury analyzed, a significantly greater proportion of animals was consistently plantar stepping (BBB≥11) or stepping with occasional coordination (BBB≥12) in the FTY720-treated group compared to the vehicle and injury-only groups. By 42 dpi, all animals in the FTY720-treated group were consistently plantar stepping, and 81.8% exhibited at least occasional coordination (BBB≥12). In contrast, only 80% of animals in the vehicle group exhibited consistent plantar stepping, and only 20% were at least occasionally coordinated.
Performance on the inclined plane mirrored open-field testing performance with the exception that differences were noted at earlier times along the study (Fig. 2B). By 14 dpi the mean difference between the treated and vehicle groups was 6.5° (35.5° versus 29°; p<0.0001). Average angles were consistently higher in the treated group for the duration of the study, and at 42 dpi the mean difference between the treated and vehicle groups was 8.6° (43.9° versus 35.3°; p<0.0001)
For both the open-field and inclined-plane tests, no significant difference in scores was detectable at any time point between the vehicle and injury-only control groups. Linear regression analysis revealed a very strong correlation between the BBB and inclined-plane scores for all time points (Fig. 2C; r=0.87).
A well-known consequence of SCI in both animals and humans is bladder dysfunction. Using an animal model of SCI, Leung and associates (2007) showed that injury severity could be directly correlated with degree of bladder dysfunction, which was reflected in the volume of urine collected during manual expression. We therefore sought to utilize bladder function as another measure of functional recovery. Figure 3A shows that all animals had impaired bladder function immediately after SCI. However, animals in the treated group had significantly lower mean urine volumes expressed compared to the vehicle and injury-only groups (n=10 for each group; p<0.0001). Post-hoc analysis also revealed no statistical difference between the vehicle and injury-only groups in terms of daily urine volumes collected.
For all animals, daily bladder expressions were performed until total daily volume collected was less than 2mL for 3 consecutive days, indicating return of spontaneous bladder function. Intergroup comparison of the number of days required to reach this milestone revealed that animals in the treated group required fewer days compared to the vehicle and injury-only groups (Fig. 3B) (6.2±0.4 versus 10.3±0.6 and 9.8±0.74; p<0.0001) No statistically significant difference was noted between the vehicle and injury-only groups.
For each urine collection, urine color was also recorded. Retrospective analysis of the incidence of gross hematuria revealed that FTY720 treatment significantly reduced the incidence of gross hematuria compared to the vehicle and injury-only groups (Fig. 3C) (45.5% versus 90% versus 100%, respectively; p<0.005 by Fisher's exact test). No difference was noted when the vehicle and injury-only groups were compared with each other.
One important aspect of assessing the utility of an immunosuppressant drug is determining whether the drug has an unacceptable level of toxicity. Many immunomodulators, although useful in their ability to reduce inflammation, are limited by their toxicity profile. Animal body weight was used as an indicator of general toxicity and monitored throughout the course of the study. Decreases in body weight can indicate failure to thrive, which would then imply drug toxicity. However, no significant differences in percentage change in body weight were noted among the three treatment groups studied (Fig. 4).
In order to correlate locomotor recovery results with histological findings, we performed myelin sparing analysis of the lesion epicenter. Animals were sacrificed at the end of the final open-field testing and spinal cords were harvested for eriochrome cyanine staining. Due to the lack of differences detected in behavioral outcome between the vehicle and injury-only groups, we confined our analysis to the treated (n=9) and vehicle groups (n=8) for comparison. The data showed that FTY720 treatment resulted in a significant increase in the percentage of myelin spared (28.5±1.6 versus 20.8±1.7, p<0.005; Fig. 5C). By linear regression analysis, final BBB scores also had a very strong correlation with the percentage of myelin spared at the epicenter (Fig. 5D; r=0.75).
The data presented in this study demonstrate that FTY720 administered after SCI dramatically reduces T-cell infiltration into the spinal cord. Furthermore, the results of behavioral outcome analyses revealed that treatment with FTY720 was effective in enhancing hindlimb and bladder recovery. Interestingly, the effect of FTY720 on hindlimb function was evident during the chronic phase of recovery, in contrast to the effect on bladder function, which was noted during the acute recovery phase. Results from morphometric analysis also provided support for the neuroprotective capacity of FTY720 and revealed that white matter preservation is enhanced with treatment.
Our initial step in establishing the efficacy of FTY720 in SCI was to determine whether treatment would affect lymphocyte infiltration into the spinal cord after injury. Analysis by flow cytometry revealed that treatment with FTY720 after SCI significantly reduced T-cell infiltration into the spinal cord (Fig. 1), whereas granulocyte and monocyte populations were relatively unaltered. These data are in agreement with previously reported studies that showed that FTY720 had differential effects on CD4+ and CD8+ T cells, and minimal effects on peripheral blood counts of granulocytes and monocytes (Kahan et al., 2003; Budde et al., 2003; Bohler et al., 2004; Quesniaux et al., 1999). The degree of lymphocyte reduction has been shown to be dose-dependent, but previously reported reduction ranges of 30–70% (Bohler et al., 2004; Quesniaux et al., 1999) are in good agreement with the data reported in this study of 50–59%.
Our flow cytometry results clearly demonstrated the efficacy of FTY720 as an immunomodulator in the post-SCI inflammatory response. However, the question remained as to whether this would have a beneficial or detrimental effect on functional recovery. Although inflammation is a well-established sequela of CNS trauma, its role in recovery has been somewhat controversial. Both beneficial and detrimental effects have been associated with the inflammatory process. Through the release of cytokines and other factors, inflammatory cell populations such as neutrophils and macrophages have long been associated with CNS toxicity (Bao and Liu, 2002; Chao et al., 1992; Donnelly and Popovich, 2008; Shamash et al., 2002). Various groups have further demonstrated that attenuation of these inflammatory mediators is beneficial and promotes neurological recovery (Beril et al., 2007; Blight, 1994; Giulian and Robertson, 1990; Gris et al., 2004; Pannu et al., 2005; Popovich et al., 1999). However, it has also been suggested that inflammation may play a dual role in neural recovery and may have significant beneficial aspects. As surveyors of the CNS, microglia have been hypothesized to have a clearing mechanism after SCI, eliminating debris and reducing the presence of any factors that might play an inhibitory role in CNS repair. These cells are known for their cytotoxic capabilities, but they have also been shown to secrete trophic factors for both neurons and glia (Banati and Graeber, 1994; Kreutzberg, 1996). There is also evidence that macrophages may have a neuroprotective role in the CNS (Yin et al., 2006; Rimaniol et al., 2000).
The concept of “protective autoimmunity” has been championed by some, with the implication that enhancement rather than attenuation of the immune response is necessary to promote CNS recovery (Schwartz and Kipnis, 2001, 2002; Yoles et al., 2001). Experimental data revealed that augmentation of the immune response via passive or active immunization with myelin basic protein limited secondary degeneration and improved functional recovery after SCI (Hauben et al., 2000, 2001). As a result, efforts have been made to design vaccines for various neurodegenerative diseases, as well as for CNS trauma (Lee et al., 1999; Schwartz, 2001). However, the concept of protective autoimmunity also runs counter to the classic concept of T cells as pathologic entities. Using T cells isolated from spinal-injured rats, Popovich and colleagues (1996) demonstrated that injection into naïve rats resulted in neurological deficits and pathology reminiscent of experimental autoimmune encephalomyelitis. Subsequent studies using transgenic mice and athymic nude rats also support the traditional view of the T cell as a pathogenic entity (Jones et al., 2002; Potas et al., 2006). Interestingly, independent efforts to replicate the original experimental vaccine protocols of Hauben and associates (2000, 2001) failed to demonstrate any benefit, and in fact revealed that functional recovery was impaired with vaccination (Jones et al., 2004). This has raised some questions regarding the safety and utility of intentionally activating CNS-reactive T cells (Popovich and Jones, 2003; Jones et al., 2004).
It is clear therefore that the only conclusion that can be made regarding the inflammatory response is that it is quite complex, and these studies only bolster the notion that the role of inflammation cannot be succinctly distilled as either beneficial or detrimental. In this study we showed that administration of FTY720 dramatically reduced T-cell infiltration into the spinal cord lesion site and enhanced locomotor recovery as well as tissue preservation after SCI. Although the locomotor enhancement observed in the open-field and inclined-plane tests was modest, frequency analysis (Table 1) of the open-field data highlighted the differences between treatment groups. By the end of the study, the vast majority of animals in the treated group (82%) exhibited at least occasional coordination, whereas only a minority of animals in the vehicle group (20%) exhibited this milestone. A previously reported study by Gonzales and colleagues (2003), using a mouse spinal hemitransection model, also showed similar results after T-cell infiltration was inhibited using a neutralizing antibody to a T-cell chemoattractant chemokine. Similarly, Ibarra and associates (2003) showed that pharmacological inhibition of T-cell responses to spinal cord antigens using cyclosporine improved functional recovery after SCI.
The results of this study would then imply that the T cells attenuated by FTY720 are deleterious to the process of recovery. Since FTY720 is not specific for all inflammatory cell populations, it may be that treatment is inhibitory to pathologic lymphocytic populations only, and not to that subset that may have a beneficial role. However, it is clear that the mechanism of action of FTY720 is not solely limited to immunomodulation. In-vitro studies have shown that FTY720 directly protects oligodendrocyte progenitor cells from apoptosis (Coelho et al., 2007). Studies have also shown that FTY720 acts on endothelial cells and helps to preserve vascular integrity and barrier function (Brinkmann et al., 2004). It is therefore possible that these actions of FTY720 on vascular integrity and oligodendrocyte cytoprotection could also play a role in the observed effects of the drug treatment.
Another observation that was made in our study was the effect of FTY720 on bladder function. Drug treatment dramatically reduced post-void residuals immediately after SCI, and reduced the number of days required to regain spontaneous bladder function. This observation suggests a direct drug effect on bladder function independent of spinal cord recovery. A link between FTY720 and bladder function is supported by in-vitro studies of rabbit bladder smooth muscle, which showed that FTY720 can regulate detrusor muscle tone (Waterson et al., 2007). We also noted a dramatic reduction in the incidence of hemorrhagic cystitis after SCI. This phenomenon is known to occur after experimental SCI, but the mechanism of this process has yet to be well characterized. Experimental studies have linked inflammatory changes in the spinal cord with disruption of bladder epithelium and hemorrhage (Apodaca et al., 2003; Doggweiler et al., 1998). Interestingly, studies have shown that FTY720 can act on endothelial cells and help to preserve vascular integrity and barrier function (Brinkmann et al., 2004). Thus it is possible that this preservation of vascular integrity is responsible for the reduced incidence of hemorrhagic cystitis observed in this study.
The effect of FTY720 on bladder function, although dramatic, represented a possible confounder and limitation of this study. Overall, fewer UTIs were diagnosed in the treated group than in the vehicle group, which was reflected in the number of antibiotic courses administered (6 versus 14, respectively). This difference is hypothesized to be due to the robust effect of treatment on bladder function. Animals that were able to void more efficiently would retain less urine and therefore be at lower risk for UTI. Theoretically, this could then confound our analysis, since improved overall systemic status could result in improved clinical scores in the open-field and inclined-plane tests. However, there was a notable disparity in the time frame in which the effects of FTY720 on locomotor scores and bladder function were noted. If the above conjecture were true, then no disparity should be present, and locomotor improvement should be noted coincident with bladder function improvement. Furthermore, there were no differences noted among treatment groups in terms of body weight change, suggesting that overall systemic status was similar among the groups. Finally, morphometric analysis also supports the neuroprotective capabilities of FTY720, as improved bladder function would presumably not result in enhanced tissue preservation in the spinal cord. Taken together this leads us to conclude that administration of FTY720 enhances locomotor function independent of bladder function and systemic status.
Our results suggest that treatment with FTY720 not only reduces the adaptive immune response, but also affords neuroprotection and enhances bladder function after injury. Given the complexity of the posttraumatic inflammatory cascade, the results of this study do not clarify the role of T cells in CNS recovery. However, these results do reinforce the growing body of knowledge suggesting immunomodulation as a possible therapeutic strategy in SCI.
We acknowledge Salem P. Wilson and Grace Lee for technical assistance. We also acknowledge Anwar Ahmed and the Department of Biostatistics for assistance with statistical analysis, and we thank Dr. T. Parsons for his editorial review of the manuscript.
The funding for this study was provided by the Lind Lawrence Foundation, as well as NIH grants no. 5T32NS007288-20 (W.N.C.), NIH-NCI R01-CA116695 (M.R.G.), and NMSS RG3432A/A2 (C.S.B.).
No conflicting financial interests exist.